LGH 20424 Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

Study of Expanded Access to Investigational Treatment for Medication Not Meeting All Standards

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

This is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel. The expanded access protocol will be used to allow subjects to receive nonconforming lisocabtagene maraleucel only if the potential benefit is better than the potential risk.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

This study investigates the use of investigational treatment for patients who receive a nonconforming version of a specific investigational medication. The purpose is to evaluate whether the potential benefits of using this nonconforming treatment outweigh the potential risks for patients.

Participants in this study will receive a nonconforming version of the investigational medication. The study is conducted at sites that are qualified and approved to provide this treatment, ensuring that all safety and procedural standards are met.

  • Who can participate: Eligibility criteria are to be determined.
  • Study details: Participants will receive a nonconforming version of the investigational medication under close supervision at approved sites.
Updated on 22 Apr 2026. Study ID: 24-1236
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator